CMV REACTIVATION AFTER STOPPING LETERMOVIR PRIMARY PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS

被引：0
|
作者：
Chavaz, Lara [1 ]
Royston, Lena [1 ]
Masouridi-Levrat, Stavroula [1 ]
Mamez, Anne-Claire [1 ]
Giannotti, Federica [1 ]
Morin, Sarah [1 ]
Van Delden, Christian [1 ]
Chalandon, Yves [1 ]
Neofytos, Dionysios [1 ]
机构：
[1] Univ Hosp Geneva, Geneva, Switzerland
来源：
BONE MARROW TRANSPLANTATION | 2023年 / 58卷 / SUPP1期
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
O102
引用
收藏
页码：93 / 93
页数：1
相关论文
共 50 条
  • [41] Clinical Efficacy of Letermovir Prophylaxis for CMV Infection after Allogeneic Hematopoietic Stem Cell Transplantation: A Single Center Experience
    Satake, Atsushi
    Ichikawa, Jun
    Saito, Ryo
    Konishi, Akiko
    Hotta, Masaaki
    Nakanishi, Takahisa
    Nakaya, Aya
    Fujita, Shinya
    Ito, Tomoki
    Ishii, Kazuyoshi
    Nomura, Shosaku
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 479 - 480
  • [42] Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience
    Lin, Andrew
    Maloy, Molly
    Su, Yiqi
    Bhatt, Valkal
    DeRespiris, Lauren
    Griffin, Meagan
    Lau, Carmen
    Proli, Anthony
    Barker, Juliet
    Shaffer, Brian
    Giralt, Sergio A.
    Jakubowski, Ann A.
    Papadopoulos, Esperanza B.
    Papanicolaou, Genovefa A.
    Seo, Susan K.
    Perales, Miguel-Angel
    TRANSPLANT INFECTIOUS DISEASE, 2019, 21 (06)
  • [43] Single center real-world data on Letermovir prophylaxis for cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation
    Derigs, P.
    Schubert, M. -L.
    Schnitzler, P.
    Mueller-Tidow, C.
    Dreger, P.
    Schmitt, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 173 - 173
  • [44] Impact of letermovir prophylaxis in CMV reactivation and disease after allogenic hematopoietic cell transplantation: a real-world, observational study
    Marc Brusosa
    Sonia Ruiz
    Inés Monge
    María Teresa Solano
    Laura Rosiñol
    Jordi Esteve
    Enric Carreras
    M. Ángeles Marcos
    Gisela Riu
    Esther Carcelero
    Carmen Martinez
    Francesc Fernández-Avilés
    Montserrat Rovira
    María Suárez-Lledó
    María Queralt Salas
    Annals of Hematology, 2024, 103 : 609 - 621
  • [45] Letermovir Resistance Genotyping in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Cell Transplant Recipients
    Douglas, Cameron M.
    Levitan, Diane
    Maguire, Maureen
    Chen, Lei
    Wei, Bo
    Barnard, Richard
    Nickle, David
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S72 - S72
  • [46] Real-world outcomes associated with letermovir use for cytomegalovirus (CMV) primary prophylaxis in allogeneic-hematopoietic cell transplant recipients: a systematic review and meta-analysis of observational studies
    Raval, A.
    Kamat, S.
    Vyas, A.
    Tang, Y.
    LaPlante, K.
    Chemaly, R.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 59 - 60
  • [47] Letermovir Resistance Genotyping in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Cell Transplant Recipients
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (04) : 8 - 10
  • [48] Letermovir Resistance in Hematopoietic Stem Cell Transplant Recipients: The Risks Associated with Cytomegalovirus Prophylaxis
    James, Scott H.
    JOURNAL OF INFECTIOUS DISEASES, 2020, 221 (07): : 1036 - 1038
  • [49] Impact of letermovir prophylaxis in CMV reactivation and disease after allogenic hematopoietic cell transplantation: a real-world, observational study
    Brusosa, Marc
    Ruiz, Sonia
    Monge, Ines
    Solano, Maria Teresa
    Rosinol, Laura
    Esteve, Jordi
    Carreras, Enric
    Marcos, M. Angeles
    Riu, Gisela
    Carcelero, Esther
    Martinez, Carmen
    Fernandez-Aviles, Francesc
    Rovira, Montserrat
    Suarez-Lledo, Maria
    Salas, Maria Queralt
    ANNALS OF HEMATOLOGY, 2024, 103 (02) : 609 - 621
  • [50] A new direction for cytomegalovirus prophylaxis among transplant recipients: Benefits and nonviral outcomes of letermovir use as primary CMV prophylaxis
    Moore, W. Justin
    Boutin, Catherine-Audrey
    Tanna, Sajal
    CURRENT OPINION IN INFECTIOUS DISEASES, 2023, 36 (06) : 514 - 521
12345